Brevan Howard Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Brevan Howard Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.08M	Buy	+3,875	New	+$1.12M	0.01%	858
2025 Q4	–	Sell	-5,592	Closed	-$1.57M	–	1816
2025 Q3	$1.57M	Sell	5,592 -16,222	-74%	-$4.41M	0.01%	678
2025 Q2	$5.26M	Buy	+21,814	New	+$5.16M	0.03%	353
2024 Q4	–	Sell	-11,083	Closed	-$3.71M	–	1056
2024 Q3	$3.71M	Buy	11,083 +8,825	+391%	+$2.8M	0.03%	162
2024 Q2	$617K	Buy	2,258 +1,403	+164%	+$408K	0.01%	535
2024 Q1	$296K	Sell	855 -552	-39%	-$182K	﹤0.01%	662
2023 Q4	$454K	Buy	+1,407	New	+$441K	0.01%	523

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brevan Howard Capital Management's BIO Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Bio-Rad Laboratories Class A (BIO) in Q1 2026: 3,875 shares worth $1.08M. The stake represents 0.01% of the portfolio and ranks #858 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in BIO as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in BIO in Q4 2023 and has held it in 7 quarters since. The position peaked at $5.26M in Q2 2025. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

Brevan Howard Capital Management held 3,875 shares of Bio-Rad Laboratories Class A worth $1.08M as of Q1 2026.
Bio-Rad Laboratories Class A was a new Brevan Howard Capital Management position in Q1 2026.
Bio-Rad Laboratories Class A made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #858 holding.
Brevan Howard Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and has held it in 7 quarters since.
Brevan Howard Capital Management's Bio-Rad Laboratories Class A position peaked at $5.26M in Q2 2025.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.